Malignant tumor of pancreas (disorder)
Clinical Trial: SPARC
Year Started: 2015
A phase 1 trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Followup records | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Physiological/biochemical measurements | 0 - 3 months |
Treatment records | 0 - 3 months |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Whole blood | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Local recurrence of malignant tumor of esophagus (disorder)
Clinical trial: Cytofloc
Year Started: 2018
Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge™) for post chemo-radiotherapy surveillance in patients with oesophageal cancer – a feasibility study
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Followup records | 0 - 3 months |
Pathology records | 0 - 3 months |
Physiological/biochemical measurements | 0 - 3 months |
Survey data | 0 - 3 months |
Treatment records | 0 - 3 months |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | Biopsy (procedure) | RT | N/A | Not applicable | 0 - 10% |
Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | Biopsy (procedure) | RT | N/A | Not applicable | 0 - 10% |
Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Barrett's esophagus (disorder)
Clinical Trial: AspECT
Year Started: 2005
AspECT: A Phase III, Randomised Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia. Trial has 10-year follow up period with samples collected throughout. Patient age groups given in the Sample Sets are the age of the patients at trial randomisation
- Access:
- Open to applicants
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Commercial restriction, DNA restriction
Associated Data Type | Procurement Timeframe |
---|---|
Followup records | 0 - 3 months |
Pathology records | 3 - 6 months |
Physiological/biochemical measurements | 0 - 3 months |
Treatment records | 0 - 3 months |
Male
Adult (> 40 years)
1001 - 3000 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 51 - 75% |
Whole blood | -60°C to -85°C | N/A | Not applicable | 51 - 75% |
Male
Young adult (18 - 40 years)
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 51 - 75% |
Whole blood | -60°C to -85°C | N/A | Not applicable | 51 - 75% |
Malignant tumor of lung (disorder)
Clinical Trial: ARCADIAN
Year Started: 2021
A phase I dose escalation study to investigate combining the antimalarial drug atovaquone with chemoradiotherapy in non-small cell lung cancer, using a time to event continual reassessment method (TiTE CRM).
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Followup records | > 6 months |
Imaging data | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | RT | Paraffin | Not applicable | 75% -99% |